v" The authors have previously reported that intracarotid infusion of 5 ug leukotriene C4 (LTC4) selectively increases blood-tumor barrier permeability in rat RG-2 tumors. In this study, rats harboring RG-2 tumors were given 15-minute intracarotid infusions of LTC4 at concentrations ranging from 0.5 ug to 50.0 #g (seven rats in each dose group). Blood-tumor and blood-brain barrier permeability were determined by quantitative autoradiography using '4C aminoisobutyric acid. The transfer constant for permeability (K0 within the tumors was increased twofold by LTC4 doses of 2.5, 5.0, and 50.0 ug compared to vehicle alone (90.00 + 21.14, 92.68 _+ 15.04, and 80.17 _+ 16.15 vs. 39.37 _+ 6.45 ul/gm/min, respectively; mean _ standard deviation; p < 0.01). No significant change in K~ within the tumors was observed at the 0.5-ug LTC4 dose. Blood-brain barrier permeability was selectively increased within the tumors. At no dose in this study did leukotrienes increase permeability within normal brain.
permeability was selectively increased within the tumors. At no dose in this study did leukotrienes increase permeability within normal brain.
To determine the duration of increased opening of the blood-tumor barrier by LTC, administration, Ki was measured at 15, 30, and 60 minutes after termination of a 15-minute LTC4 infusion (seven rats at each time point). The mean K~ value was still high at 15 minutes (92.68 ___ 15.04 ul/gm/min), but declined at 30 minutes (56.58 _+ 12.50 ul/gm/min) and 60 minutes (55.40 + 8.10 ul/gm/min) after the end of LTC4 infusion.
Sulfidopeptide leukotrienes LTC4, LTD4, LTE4 and LTF4 were infused to compare their potency in opening the blood-tumor barrier. The mean leukotriene E4 was the most potent, increasing the permeability value 3 89 fold compared with vehicle alone (139.86 + 23.95 vs. 39.37 _+ 6.45 ~l/gm/min).
KEy WOADS 9 leukotriene 9 brain neoplasm 9 blood-brain barrier 9 rat T HE blood-tumor barrier within the capillaries of primary brain tumors is considered to be an obstacle to delivering water-soluble antineoplastic agents to brain-tumor tissue. 1~
One approach to brain tumor therapy has therefore focused on methods that open or modify the brain-tumor barrier and increase drug delivery. In a previous study, we demonstrated that leukotriene C4 (LTC4) infused into the carotid artery ipsilateral to experimental RG-2 glial tumors in rats increased the unidirectional transfer constant for permeability (Ki) twofold within the tumors, while no effect on permeability was seen in normal brain. 6 Based on this observation, we suggested that LTC4 may be useful clinically in selectively increasing the delivery of antineoplastic agents to tumors. The purpose of this study was to determine the optimal dose and the duration of opening of the blood-tumor barrier by LTC4 administration. The potencies of various sulfidopeptide leukotrienes (LTC4, LTD4, LTE4, and LTF4) were also compared.
Materials and Methods
Eighty-four female Wistar rats, each weighing 130 to 170 gm, were used for this study. The sulfidopeptide leukotrienes* were obtained at a concentration of 0.1 mg/ml in a 1:1 phosphate-buffered saline (PBS)-ethanol solution. Aliquots of LTCa, LTDa, LTE4, and LTFa were diluted to experimental concentrations in PBS and the final ethanol concentration was adjusted to 2.5%. Vials containing the leukotrienes were sealed under nitrogen and stored at -80"C. Alpha-[ 1-14C]-aminoisobutyric acid (AIB) (57.6 mCi/mmol)t was used for quantitative autoradiographic study.
Tumor Inoculation
The RG-2 glioma cells were maintained in a monolayer culture in F-12 medium with 10% calf serum., The rats were anesthetized with intraperitoneal pentobarbital sodium (Nembutal, 40 mg/kg). Tumor cells (5 • 105 in a 5-ul solution) were stereotactically implanted by means of a Hamilton syringe into the right cerebral * Leukotrienes supplied by Cayman Chemicals, Ann Arbor, Michigan.
~" Alpha-[ 1-~4C]-aminoisobutyric acid supplied by New England Nuclear, Boston, Massachusetts.
F-12 medium and 10% calf serum supplied by GIBCO, Grand Island, New York.
hemisphere 5 mm lateral to the bregma and 5 mm deep to the dural surface.
Dose Response Study
Ten to 11 days after tumor implantation, the rats were again anesthetized and a polyethylene (PE-50) catheterw was inserted retrograde through the external carotid artery to the common carotid artery bifurcation ipsilateral to the tumor. The external carotid artery was then ligated, and both femoral arteries and one femoral vein were cannulated. Body temperature was mainmined at 37"C. Arterial blood gas levels, blood pressure, and hematocrit were monitored. Animals with abnormal physiological parameters were eliminated from the study. Infusions of LTC4 at concentrations of 0.5, 2.5, 5.0, and 50.0 ug/0.8 ml or 0.8 ml of vehicle (2.5% ethanol in PBS, pH 7.1) were administered into the fight carotid artery of seven rats in each dose group using a constant-infusion pump]l at a rate of 53.3 ul/ min for 15 minutes. Five minutes after the start of the intracarotid infusion, an intravenous bolus of 100 uCi/ kg of ~4C-AIB was delivered. A peristaltic withdrawal pump* was used to withdraw femoral arterial blood at a constant rate of 0.083 ml/min immediately after injection of ~4C-AIB for determination of serum radioactivity. Fifteen minutes after the start of intracarolid infusions, the animals were killed by decapitation and the brains were rapidly removed and frozen.
Time Course Study
Ten to 11 days after tumor implantation, the rats were cannulated and physiological parameters were measured as described above. An intracarotid infusion of 0.8 ml LTC4 at a dose of 5 ug was delivered for 15 minutes, and K~ was measured at 15, 30, and 60 minutes after the termination of LTC4 infusion.
Potency of Leukotrienes
Various sulfidopeptide leukotrienes (LTC4, LTD4, LTE4, and LTFa), at a dose of 5 ug, were infused for 15 minutes into seven rats in each leukotriene group and the Ki value was measured as described above.
Autoradiography
The frozen rat brains were mounted onto pedestals with M-1 embedding matrix,t and 20-urn coronal sections were cut using a cryotome. The sections were thaw-mounted onto coverslips, and autoradiograms were generated by coexposing the sections on Kodak XAR-5 film with tissue-calibrated 14C 
Definition of Regions
For K~ measurements, the tumor periphery was defined as the outer half of the tumor radius, the tumor center as the inner half of the tumor radius, and brain adjacent to tumor as an area of the adjacent basal ganglia in the vascular territory of the lenticular striate vessels.
Data Analysis
The K~ values for the experiments were calculated by measuring the three regions of interest described above in three consecutive sections. Analysis of variance and unpaired Student's t-test were applied to the mean values from separate experiments.
Results

Physiological Status
Arterial blood gas levels were measured in all rats used in the experiments. The mean pH, PaCO2, and PaO2 were 7.394 _+ 0.056, 37.6 4-5.5 mm Hg, and 96.8 _+ 12.2 mm Hg, respectively (_+ standard deviation). The mean arterial pressure was 132 + 16.8 mm Hg and the hematocrit was 36.2% __ 6.2%. The physiological parameters were not altered after leukotriene infusion.
Brain Tumor Size
The size of the rat brain tumors was measured in the histological section with the largest tumor area. The average size was 9.2 _+ 3.1 sq mm, and there was no statistically significant difference among the subgroups. (Fig. 1) . No acute side effects were seen in the rats, even in those receiving the 
Dose Response Study
Time Course Study
Fifteen minutes after the termination of LTC4 infusion, the mean Ki value remained elevated by almost twofold compared with vehicle alone (92.68 _+ 15.04 vs. 39.37 + 6.45 ul/gm/min). The mean Ki value significantly declined after 30 and 60 minutes (56.58 _+ 12.50 and 55.40 ___ 8.10 ul/gm/min, respectively) compared with that after 15 minutes (p < 0.01) (Fig. 2) .
Potency of Leukotrienes
All sulfidopeptide leukotrienes (LTC4, LTD4, LTE4, and LTF4) increased the mean Ki value within the tumors significantly compared to vehicle alone (92.68 _+ 21.14, 84.19 + 22.16, 139.86 + 23.95, and 100.35 _+ 11.00 vs. 39.37 +_ 6.45 ul/gm/min, respectively; p < 0.01). The most potent was LTE4, which increased the Ki value within the tumors about 3 89 (Fig. 3) .
Discussion
Leukotrienes are metabolites of arachidonic acid generated via the 5-1ipoxygenase pathway. Levels of leukotrienes in brain tissue are increased during postischemic reperfusion ~5 and in brain tumors, 5 subaraehnoid hemorrhage, and concussive brain injury. ~ We previously showed a correlation between LTC4 levels and brain edema surrounding tumors in man? Gaetani, et al. , ~j also demonstrated that perilesional brain tissue has a significant capacity for an ex vivo synthesis of eicosanoids, and the capacity to synthesize LTC4 is significantly correlated with the extent of edema, particularly in cases of neuroepithelial and metastatic tumors. Leukotrienes have also been suggested to be biochemical mediators of ischemic brain edema5 "s,9 '4 In a prior study, we incorrectly suggested that the intracerebral injection of high doses of leukotrienes in rats increased BBB permeability in normal brain. 3'4 Intracerebral injections of leukotrienes in these studies did not in fact increase permeability in normal brain; however, permeability did increase under the area where drilling for the burr hole had occurred, suggesting that injury to brain is prerequisite for leukotrienes to increase permeability.
Subsequently, we have demonstrated that intracarot- id infusion of L]'C4 selectively increases capillary permeability in tumors and ischemic brain but not in normal brain, z,6 This may be due in part to the fact that normal brain capillaries, unlike systemic capillaries, contain high concentrations of the enzyme gamma glutamyl transpeptidase. This enzyme inactivates LTC4 and LTE4 and is lost in brain tumor capillaries and in brain capillaries after ischemia. 26 In effect, normal brain capillaries, unlike capillaries within brain-tumor tissue or ischemic brain, appear to have an "enzymatic barrier" to protect them against the vasoactive effects of leukotrienes.
Neuwelt and coworkers 17-2~ have shown that osmotic barrier disruption with hypertonic mannitol will nonselectively increase the delivery of chemotherapeutic agents and monoclonal antibodies to brain tissue in humans. However, osmotic disruption of the BBB results in a large increase in drug delivery to normal brain. 16 One advantage of leukotrienes selectively opening the blood-tumor barrier is that it leaves the barrier in normal brain intact, 6 protecting normal brain from the adverse effect of antitumor compounds.
This study extends our prior report, which demonstrated the ability of LTC4 to selectively open the bloodtumor barrier. The optimal dose range of LTC4 infusion for increasing permeability in rat RG-2 tumors is 2.5 ug or 5.0 #g. Opening of the blood-tumor barrier is reversible and decreases significantly 30 minutes after termination of LTC4 infusions. Leukotriene E4 appears to be the most potent sulfidopeptide leukotriene to open the blood-tumor barrier.
